Diclofenac Sodium Gel 3%

Topical Solution 3% – 100 g (12 units)
NDC #: 45861-0063-01


Diclofenac Sodium Gel 3% elevates the benefits of its active ingredient from beyond pain relief to the prevention of skin cancer. Ten years of clinical data reveals that patients sustain long-term clearance of precancerous lesions and that Diclofenac Sodium 3% Gel is better tolerated and has comparable efficacy with 5-fluorouracil 5% and imiquimod 5%. 1 It’s also effective in immunosuppressed populations.

Pharmaceutica North America is proud to be the premier supplier of Diclofenac Sodium Gel 3% and one of the nation’s leading compounding pharmaceutical companies. Our team is honored to collaborate with you, whether that means navigating the safe and timely delivery of products, or working to develop a unique administration system.

Approved and Potential Uses of Sodium Diclofenac Gel 3%:  

In addition to acting as an inhibitor of cyclooxygenase enzymes 1 and 2, preclinical research indicates that Diclofenac Sodium Gel 3% inhibits angiogenesis and induces apoptosis. Consider using it for the following conditions:

  • Actinic keratosis, or solar keratosis – Diclofenac Sodium Gel 3% is currently only approved to treat the scaly, crusted lesions of actinic keratosis (AK), which are caused by sunlight and can progress to become squamous cell carcinoma. Following a 90-day course of treatment, 91 percent of patients had 75 percent clearance of AK lesions after one year, while 70 percent had 100 percent clearance, according to the Phase 4 multicenter trial. 2
  • Basal cell carcinoma – Topical Diclofenac 3% Gel is a promising treatment for basal cell carcinoma (BCC). It offers a unique method of action compared to other topical treatments for BCC, with the added benefit of fewer and milder adverse effects.
  • Actinic porokeratosis – Disseminated superficial actinic porokeratosis (DSAP) is a chronic cutaneous disorder of keratinization. Diclofenac Sodium Gel 3% is emerging as a potential treatment that slows lesion progression and is tolerated by patients.

When you purchase Diclofenac Sodium Gel 3% from Pharmaceutica North America, you’re guaranteed competitive pricing and a stable product that was manufactured and distributed in accordance with cGMP at an FDA and DEA registered facility. Contact us today to learn about our fast shipping and how we can work together to ensure high-quality pharmaceutical products for your clients.

Diclofenac Sodium Gel 3% Fact Sheet


Show 2 footnotes

  1. “Diclofenac Sodium 3% Gel for the Management of Actinic Keratosis: 10+ Years of Cumulative Evidence of Efficacy and Safety,” May 2012, https://www.ncbi.nlm.nih.gov/pubmed/22527428
  2. “Long-Term Follow Up of Diclofenac Sodium 3 Percent in 2.5 Percent Hyaluronic Acid Gel for Actinic Keratosis: One-Year Evaluation,” July 2009, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924138/